Molecular mechanisms to form leukocyte infiltration patterns distinct between synovial tissue and fluid of rheumatoid arthritis

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 6, 1996, Pages 507-511

  Yamamoto, Tetsuro ^a   Nishiura, Hiroshi ^a   Nishida, Hidefumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

C4a anaphylatoxin; leukocyte infiltration; monocyte chemotactic factor; rheumatoid arthritis; S19 ribosomal protein

Indexed keywords

COMPLEMENT COMPONENT C4A; MONOCYTE CHEMOTACTIC PROTEIN; RIBOSOME PROTEIN;

CHEMOTAXIS; HUMAN; LEUKOCYTE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

EID: 0030454122     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999052     Document Type: Review

References (34)

1. Colvin RB, HF Dvorak: Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reactions. J Immunol 114: 377-387. 1975.
2. Weinberg JB, AM Pippen, CS Greenberg: Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheumatol 34:996-1005, 1991.
3. Hogg N: Human monocytes are associated with the formation of fibrin. J Exp Med 157:473-485, 1983.
4. Imamura T, K Iyama, M Takeya, T Kambara, S Nakamura: Role of macrophage tissue factor in the development of the delayed hypersensitivity reaction in monkey skin. Cell Immunol 152:614-622, 1993.
5. Popert AJ, DL Scott, AC Wainwright, KW Walton, N Williamson, JH Chapman: Frequency of occurrence, mode of development, and significance of rice bodies in rheumatoid joints. Ann Rheum Dis 41:109-117, 1982.
6. Matsubara S, T Yamamoto, T Tsuruta, K Takagi, T Kambara: Complement C4-derived monocyte-directed chemotaxis-inhibitory factor; a molecular mechanism to cause polymorphonuclear leukocyte-predominant infiltration in rheumatoid arthritis synovial cavities. Am J Pathol 138:1279-1291, 1991.
7. Plow EF, TS Edgington: An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56:30-38, 1975.
8. Kummer JA, JJ Abbink, J-P DeBoer, D Roem, EDJ Nieuwenhuys, AM Kamp, TJG Swaak, CE Hack: Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint disease. Arthritis Rheumatol 35:884-893, 1992.
9. Goetzl EJ: Modulation of human neutrophil polymorphonuclear leukocytes migration by human plasma alpha-globulin inhibitors and synthetic esterase inhibitors. Immunology 29:163-174, 1975.
10. Perez HD, C Hooper, J Volankis, A Ueda: Specific inhibitor of complement (CS)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B. J Immunol 139:484-489, 1987.
11. Tsuruta T, T Yamamoto, S Matsubara, S Nagasawa, S Tanase, J Tanaka, K Takagi, T Kambara: Novel function of C4a anaphylatoxin; release from monocytes of protein which inhibits monocyte chemotaxis. Am J Pathol 142:1848-1857, 1993.
12. Nishiura H, Y Shibuya, S Matsubara, S Tanase, T Kambara, T Yamamoto: Monocyte chemotactic factor in rheumatoid arthritis synovial tissue; probably a cross-linked derivative of S19 ribosomal protein. J Biol Chem 271:878-882, 1996.
13. Kondoh N, CW Schweinfest, KW Henderson: Differential expression of S19 ribosomal protein, laminin-binding protein, and human lymphocyte antigen class I messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res 52: 791-796, 1992.
14. Eitan S, M Schwartz: A transglutaminase that converts interleukin-2 into a factor cytotoxic to oligodendrocytes. Science 261:106-108, 1993.
15. Fernandez HN, PN Henson, A Otani, TE Hugli: Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro under simulated in vivo conditions. J Immunol 120:109-115, 1978.
16. Wolff T, DF Ready: Cell death in normal and rough eye mutants of Drosophila. Development 113:825-839, 1991.
17. Knight CRL, RC Rees, M Griffin: Apoptosis: A potential role for cytosolic transglutaminase and its importance in tumour progression. Biochim Biophys Acta 1096:312-318, 1991.
18. Kinne RW, E Palombo-Kinne, F Emmrich: Activation of fibroblast in rheumatoid arthritis. Ann Rheum Dis 54:501-504, 1995.
19. Defacque H, T Commes, V Contet, C Sevilla, J Marti: Differentiation of U937 myelomonocytic cell line by all-trans retinoic acid and 1,25-dihydroxyvitamin D3: Synergistic effects on tissue transglutaminase. Leukemia 9:1762-1767, 1995.
20. Kukita I, T Yamamoto. T Kawaguchi, T Kambara: Fifth component of complement (C5)-derived high-molecular-weight macrophage chemotactic factor in normal guinea pig serum. Inflammation 11:459-479, 1987.
21. Okamoto M, T Yamamoto, S Matsubara, I Kukita, M Takeya, Y Miyauchi, T Kambara: Factor XIII-dependent generation of 5th complement component (C5)-derived monocyte chemotactic factor coinciding with plasma clotting. Biochim Biophys Acta 1138: 53-61, 1992.
22. Bendixen E, W Borth, PC Harpel: Transglutaminase catalyzed cross-linking of plasminogen to fibronectin and human endothelial cells. J Biol Chem 268:21962-21967, 1993.
23. Freer RJ, AR Day, JA Radding, E Schiffmann, S Aswanikumar, HJ Showell, EL Becker: Further studies on structural requirement for synthetic peptide chemoattractants. Biochemistry 19:2404-2410, 1980.
24. Müller-Eberhard HJ, IH Lepow: C'l esterase effect on activity and physicochemical properties of the fourth component of complement. J Exp Med 121:819-833, 1965.
25. - generation by C4a. Immunol Lett 36:301-304, 1993.
26. Gorski JP, TE Hugli, HJ Müller-Eberhard: C4a; the third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 76:5299-5302, 1979.
27. Payan DG, DE Trentham, EJ Goetzl: Modulation of human lymphocyte function by C3a and C3a (70-77). J Exp Med 156:756-765, 1982.
28. Mollison KW, W Mandecki, ERP Zuiderweg, L Fayer, TA Fey, RA Krause, RG Conway, L Miller, RP Edalji, MA Shallcross, B Lane, JL Fox, J Greer, GW Carter: Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci USA 86:292-296, 1989.
29. Cooper NR The classical complement pathway; activation and regulation of the first complement component. Adv Immunol 37: 151-216, 1985.
30. Carson DA, PP Chen, RI Fox, TJ Kipps, F Jirik, ED Goldfine, G Silverman, V Radoux, S Fong: Rheumatoid factors and immune network. Annu Rev Immunol 5:109-126, 1987.
31. Wild G, J Watkins, AM Ward, P Hughes, A Hume, NR Rowell: C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol 80:167-170, 1990.
32. Bokisch VA, HJ Müller-Eberhard: Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest 49:2427-2436, 1970.
33. Plummer TH Jr, MY Hurwitz: Human plasma carboxypeptidase N: Isolation and characterization. J Biol Chem 253:3907-3912, 1978.
34. Campbel W, K Yonezu, T Shinohara, H Okada: An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis. J Lab Clin Med 115:610-612, 1990.